Today's Rundown Amgen R&D head Harper to leave for new pastures Achaogen wields ax on R&D, C-suite as antibiotic launch nears Sutro Biopharma nets $85.4M to drive antibody-drug conjugates [Sponsored] Q&A with Cardinal Health Regulatory Sciences: Navigating cell and gene therapies through clinical and regulatory hurdles Muscle discovery could open new treatment paths for ALS and other neuron disorders Genentech’s first implantable drug delivery system shows promising results in phase 2 wet AMD trial EuroBiotech Report—AstraZeneca cancer trial, GSK attempts R&D turnaround, Sanofi digital investment and more FiercePharmaAsia—Biogen-Eisai Alzheimer’s data, China vaccine scandal, BMS-Tsinghua deal Chutes & Ladders—Gilead's 2 top executives step down Featured Story | | | Friday, July 27, 2018 Amgen’s R&D head, Sean Harper, announced he is stepping down from the big biotech to pursue new opportunities in startups and early-stage companies. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Friday, July 27, 2018 The impact of Achaogen’s narrower-than-expected label for antibiotic Zemdri is now apparent: The biotech has slashed 28% of its staff and all but two R&D programs. Thursday, July 26, 2018 Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates. Monday, July 23, 2018 Gene and cell therapies are at the cutting-edge of biomedical research, promising potentially curative options for a host of disorders such as forms of blindness, blood cancers and inherited diseases. Thursday, July 26, 2018 Cells that promote muscle repair have a dark side—a tendency to change so radically that they actually cause wasting and scarring rather than healing. Blocking the pathway that causes this could offer a new way to treat neurological disorders. Thursday, July 26, 2018 Genentech’s investigational, refillable eye implant—designed to deliver a new formulation of Lucentis' active ingredient, ranibizumab, continuously to wet age-related macular degeneration patients—showed positive results in a phase 2 trial compared to the traditional delivery method. Thursday, July 26, 2018 In this week's EuroBiotech Report, AstraZeneca sees its Array-licensed MEK drug fail in another cancer setting; GlaxoSmithKline, armed with new research personnel, guns for the immune system and a new R&D philosophy with a new pact with 23andMe; plus more. Friday, July 27, 2018 Eisai and partner Biogen's recent Alzheimer's data has failed to impress investors; the Chinese government is scrambling to contain a vaccine scandal that sparked anger and fear among citizens; Bristol-Myers and Tsinghua University have penned a drug discovery pact in cancer and autoimmune diseases; and more. Friday, July 27, 2018 Gilead's two top executives step down, Amgen's R&D head leaves for the startup scene and BMS' commercial chief jumps ship to head for Amgen. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is IQVIA. | | | |
Resources Sponsored by: Veeva Industry Research: See new results from one of the industry's largest, global clinical operations surveys. Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Medidata Accelerate Clinical Research as Study Complexity Grows Sponsored by: Patheon, part of Thermo Fisher Scientific Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy. Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online The Life Science Women's Conference August 8-9, 2018 | Austin, Texas Join 200+ Service and Support Leaders at Field Service Amelia Island this August August 27-29, 2018 | Amelia Island, FL BIO Latin America 2018 September 4-5, 2018 | São Paulo, Brazil RESI HealthTech Week September 5-7, 2018 | Boston, MA 2018 Latin America Healthcare Compliance Certification Program Sao Paulo, Brazil | Sep 24-27, 2018 4th Annual Bio/Pharmaceutical Product Launch Summit September 25-26, 2018 | Cambridge, MA Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA The Advanced Biologic Development Summit at Northeastern University October 9, 2018 | Boston, MA BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL 2018 BIO Investor Forum October 17-18, 2018 | Westin St. Francis, San Francisco, CA FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation |
